Drug Patents owned by Wyeth Pharms
1. Drug name - DUAVEE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7683051 | WYETH PHARMS | Crystalline polymorph of bazedoxifene acetate |
Mar, 2027
(4 years from now) | |
| CN1938272A | WYETH PHARMS | The Crystal Polymorphic Form Of The Bazedoxifene Acetate |
Jan, 2010
(12 years ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6479535 | WYETH PHARMS | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
May, 2024
(1 year, 7 months from now) | |
Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient
Treatment: Prevention of postmenopausal osteoporosis; treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE;0.45MG | TABLET;ORAL | Prescription |
2. Drug name - PROTONIX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7838027 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 11 months from now) | |
| US7550153 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 11 months from now) | |
| US7553498 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 11 months from now) | |
|
US7553498
(Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(2 years from now) | |
|
US7550153
(Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(2 years from now) | |
|
US7838027
(Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(2 years from now) | |
| US7544370 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Jun, 2026
(3 years from now) | |
|
US7544370
(Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Dec, 2026
(4 years from now) | |
Drugs and Companies using PANTOPRAZOLE SODIUM ingredient
Treatment: Erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerd
Dosage: FOR SUSPENSION, DELAYED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 40MG BASE | FOR SUSPENSION, DELAYED RELEASE;ORAL | Prescription |
3. Drug name - ZOSYN
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8133883 | WYETH PHARMS | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(6 months from now) | |
| US6900184 | WYETH PHARMS | Compositions containing pipercillin and tazobactam useful for injection |
Apr, 2023
(6 months from now) | |
| US7915229 | WYETH PHARMS | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(6 months from now) | |
Drugs and Companies using PIPERACILLIN SODIUM; TAZOBACTAM SODIUM ingredient
Treatment: Method of treating bacterial infections
Dosage: INJECTABLE;INJECTION
| Strength | Dosage | Availability |
|---|---|---|
| EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL | INJECTABLE;INJECTION | Discontinued |
| EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL | INJECTABLE;INJECTION | Discontinued |
| EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL | INJECTABLE;INJECTION | Discontinued |
| EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL | INJECTABLE;INJECTION | Discontinued |
4. Drug name - ZOSYN IN PLASTIC CONTAINER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7915229 | WYETH PHARMS | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(6 months from now) | |
| US8133883 | WYETH PHARMS | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(6 months from now) | |
| US6900184 | WYETH PHARMS | Compositions containing pipercillin and tazobactam useful for injection |
Apr, 2023
(6 months from now) | |
Drugs and Companies using PIPERACILLIN SODIUM; TAZOBACTAM SODIUM ingredient
Treatment: Method of treating bacterial infections
Dosage: INJECTABLE;INJECTION
| Strength | Dosage | Availability |
|---|---|---|
| EQ 4GM BASE/100ML;EQ 500MG BASE/100ML | INJECTABLE;INJECTION | Prescription |
| EQ 40MG BASE/ML;EQ 5MG BASE/ML | INJECTABLE;INJECTION | Prescription |
| EQ 60MG BASE/ML;EQ 7.5MG BASE/ML | INJECTABLE;INJECTION | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.